ASCO 2019: Maintenance therapy with PARP inhibitor olaparib delays progression of BRCA-related pancreatic cancer
The randomised, phase III POLO trial found that maintenance therapy with the PARP inhibitor olaparib…
Browsing: POLO trial
Olaparib significantly delayed disease progression as first-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer
Results from the Phase III POLO trial showed a statistically significant and clinically meaningful improvement…